ClinicalTrials.gg
Sign In
CompletedNCT02708056Updated Mar 15, 2016

Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

A Phase 4 interventional study of Sugammadex in Brain Cancer, sponsored by Baskent University. Completed. Open to participants aged 1 Month to 12 Months. Per ClinicalTrials.gov, last updated 2016-03-15.

Sponsored by Baskent University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
1 Month to 12 Months
Sex
All
01

Study summary

The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

02

Conditions studied

  • Brain Cancer

Browse trials for

Keywords

  • Sugammadex
  • Rocuronium
  • Infant patients
03

In context

Brain Neoplasms

1,993 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.

This study's enrollment of 26 is below the median of 40 across 1,479 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

Baskent University is the lead sponsor of 209 studies on the registry; 35 are open to participants now.

Browse Baskent University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between the ages of 1-12 month,
  • ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study

Exclusion criteria

Exclusion Criteria:

  • younger than 1month or older than 12 months.
  • hepatic or renal failure
  • A history of allergy to study medication
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Other
    Sugammadex, Bridion

    Drug were given intravenously by a anesthesiologist at the end of surgery

    Drug: Sugammadex

Interventions

06

What researchers measure

Primary outcomes

  1. The efficacy of sugammadex were assessed by using Train of four (TOF)

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2016
First posted
Mar 15, 2016
Start
Jan 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Mar 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02708056
Lead sponsor
Baskent University
Responsible party
Ozlem Ozmete (Medical Doctor, Baskent University) — Principal investigator
First posted
Mar 15, 2016
Start date
Jan 2015
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Mar 15, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sugammadex

Other studies in this condition

Brain Neoplasms →

Other studies from this sponsor

Baskent University →

Start the discussion